Current Report Filing (8-k)
May 14 2020 - 1:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
|
Date of
Report (Date of earliest event reported):
|
|
May 11, 2020
|
PREMIER BIOMEDICAL, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-54563
|
|
27-2635666
|
(State
or other jurisdiction of
incorporation)
|
|
|
|
(I.R.S.
Employer
Identification
No.)
|
|
|
|
|
|
|
|
P.O. Box 25
Jackson Center, PA 16133
(Address
of principal executive offices) (zip code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(814) 786-8849
(Registrant’s
telephone number, including area code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Former
name or former address, if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[_]
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[_]
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_]
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company
[_]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[_]
Section 1 – Registrant’s Business and
Operations
Item 1.01
Entry into a Material Definitive Agreement.
Joint Ventures to Research COVID-19 Treatment
In
April 2020, we signed a joint venture agreement with two other
companies to pursue the funding and research and development on our
patented extracorporeal therapy for the safe removal of targeted
antigens from the blood and targeted organs. In the case of
COVID-19, this entails removal of specific compounds which allow
the virus to replicate, which may eliminate mutations of the virus.
In preparation for the joint venture, we filed a new provisional
patent entitled “Method for
Treating and Curing COVID-19 Infection.” Following the
start of the joint venture, we filed another provisional patent
entitled “Method for Treating
Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity
and Mortality in Covid-19 Patients”. It is too early to tell whether these
technologies will have any practical
application.
On May 12, 2020, we assigned our rights
in these two patents to Technology Health, Inc. pursuant to an
Intellectual Property Agreement in hopes that they will be able to
finance and develop the technologies. The assignment is part of an
agreement with Technology Health, Inc., and two other companies to
pursue a novel coronavirus extracorporeal treatment which combines
our antigen mapping technique with Datatecnics’ laser
ablation technology in a focused “Map and
ZapTM”
treatment protocol disclosed in a provisional patent application
that is intended to eliminate COVID-19 antigens and potential
mutations. Research is expected to start in the second quarter of
2020 to develop complexing agents to bind with coronavirus antigens
which can be illuminated and eliminated using a computer-controlled
targeting and laser system. The proposed hospital/clinic process
would illuminate the compounded molecular target disease antigens
for destruction by a nano-focus laser, and the purified blood would
then be returned to the patient.
Section 9 – Financial Statements and Exhibits.
Item 9.01 Financial Statements and Exhibits.
|
|
|
Technology
Acquisition and Financing Agreement dated May 8, 2020
|
|
|
|
|
|
|
|
Intellectual
Property Agreement dated May 12, 2020
|
|
|
|
|
|
|
|
Third
Addendum to License Agreement with Marv Enterprises, LLC dated May
11, 2020
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Premier Biomedical, Inc.
|
|
|
|
|
|
|
|
Dated:
May 14, 2020
|
/s/
William Hartman
|
|
|
By:
William Hartman
|
|
|
Its: Chief
Executive Officer
|
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Premier Biomedical (PK) (USOTC:BIEI)
Historical Stock Chart
From Nov 2023 to Nov 2024
